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Background: Moyamoya disease (MMD) is an uncommon cerebrovascular condition with unknown etiology
characterized by slowly progressive stenosis or occlusion of the bilateral internal carotid arteries associated with an
abnormal vascular network. MMD is a major cause of stroke, specifically in the younger population. Diagnosis is
based on only radiological features as no other clinical data are available. The purpose of this study was to identify
novel biomarker candidate proteins differentially expressed in the cerebrospinal fluid (CSF) of patients with MMD
using proteomic analysis.
Methods: For detection of biomarkers, CSF samples were obtained from 20 patients with MMD and 12 control
patients. Mass spectral data were generated by surface-enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF-MS) with an anion exchange chip in three different buffer conditions. After expression
difference mapping was undertaken using the obtained protein profiles, a comparative analysis was performed.
Results: A statistically significant number of proteins (34) were recognized as single biomarker candidate proteins
which were differentially detected in the CSF of patients with MMD, compared to the control patients (p < 0.05).
All peak intensity profiles of the biomarker candidates underwent classification and regression tree (CART) analysis
to produce prediction models. Two important biomarkers could successfully classify the patients with MMD and
control patients.
Conclusions: In this study, several novel biomarker candidate proteins differentially expressed in the CSF of
patients with MMD were identified by a recently developed proteomic approach. This is a pilot study of CSF
proteomics for MMD using SELDI technology. These biomarker candidates have the potential to shed light on the
underlying pathogenesis of MMD.
Background
Moyamoya disease (MMD) is characterized by progressive
stenosis or occlusion of the bilateral internal carotid
arteries associated with compensatory abnormal vascular
network, so called moyamoya vessels [1]. A Japanese sur-
vey of 2075 patients with MMD found an annual inci-
dence of 0.35, annual prevalence of 3.16 per 100,000 and a
tendency of occurrence in the younger generation [2].
According to a world distribution analysis, a relatively
large number of patients with MMD are present in East
Asia, but rarely in Europe and the Americas [3]. Such
regional and racial differences in susceptibility and familial
occurrence in 10% of MMD cases [4] suggest that a
genetic predisposition may be associated with the etiology
and pathogenesis of this disease. Both 3p24-26 [5] and
8q23 [6] in genome-wide analyses, in addition to both
6q25 (D6S441) [7] and 17q25 [8] in chromosomal level
analyses, have been identified in familial MMD and were
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stenosis or occlusion of internal carotid arteries has been
attributed to eccentric fibrocellular thickening of the
intima following proliferation and necrosis of smooth
muscle cells, which are associated with the thinning of the
media [9,10]. These processes are reported to be regulated
by the expression of several growth factors related to
angiogenesis: transforming growth factor-b [11], basic
fibroblast growth factor [12], hepatocyte growth factor
[13], hypoxia inducible factor-1 [14] and vascular endothe-
lial growth factor [15]. An increasing number of reports
have been focusing on not only angiogenesis related to
growth factors but vasculogenesis. Vasculogenesis is con-
sidered the pathway for adult neovascularization, which
induces the formation of new blood vessels from circulat-
ing bone marrow-derived endothelial progenitor cells
rather than from local endothelial cells regulated by
growth factors [16,17]. It has been hypothesized that aber-
rant vasculogenesis contributes to vascular abnormalities
including MMD [18]. Despite the establishment of
approaches for clarifying the disease mechanisms of
MMD, the direct underlying pathogenesis remains
unclear. One approach utilizing proteomics has revealed
disease-associated proteins as novel biomarkers and char-
acterized their function in pathogenesis and development
of the disease [19,20]. Among the many different types of
approaches for CSF investigation [21], SELDI-TOF-MS
technology [22] allows for high-throughput analysis of
samples with diverse functionalization on surfaces (Pro-
teinChip, Bio-Rad Laboratories, Hercules, CA, USA) and
has been successfully used to identify protein profiles of
central nervous system disorders [23,24]. The objective of
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For proteomic analysis, CSF samples were prospectively
collected from a consecutive sequence of 20 patients with
MMD (11 male and 9 female; mean age, 21 years; range 1-
54 years) admitted to Nagoya University Hospital, Nagoya,
Japan, between February 2008 and December 2009. Diag-
nosis of MMD was determined by cerebral angiography or
magnetic resonance imaging/angiography according to the
guidelines set by the Research Committee on Moyamoya
Disease (Spontaneous Occlusion of Circle of Willis) of the
Ministry of Health and Welfare of Japan [25]. Type of
onset of MMD includes 12 transient ischemic attacks, four
cerebral infarctions, one hemorrhage and two asympto-
matic cases. According to the guidelines for the diagnosis
of MMD, “definite MMD” cannot have originated from
any other underlying disease; the presence of an associated
disease is classified as “quasi-MMD”.O nt h eo t h e rh a n d ,
for proteomic analysis of the CSF used in this study,
results are thought to be unsusceptible to the underlying
disease. That is, both classifications of the disease (definite
or quasi) have similar clinical characteristics and treat-
ments. Therefore, two of the patients in this study present-
ing with Down syndrome were categorized as MMD
(Table 1). As controls, 12 patients were recruited from
among those admitted to Nagoya University Hospital for
Table 1 Clinical characteristics of each patient group in this study
No. of patients (%)
MMD Controls P value
Variables n = 20 n = 12
Age Mean ± SD, years 20.5 ± 17.4 61.2 ± 9.1 <0.01
Sex, n (%)
Male 11 (55.0) 3 (25.0) 0.1
Female 9 (45.0) 9 (75.0)
Type of onset, n (%) NA
TIA 12 (60.0)
Infarction 4 (20.0) 2 (16.7)
Hemorrhage 1 (5.0)
Asymptomatic 2 (10.0) 7 (58.3)
Others 1 (5.0) 3 (25.0)
Associated disease, n (%) NA
None 18 (90.0)
Down syndrome 2 (10.0)
Cerebral aneurysm 9 (75.0)
Others 3 (25.0)
Suzuki’s angiographycal stage (1-6) Mean ± SD 3.05 ± 0.9 NA
TIA, transient ischemic attack; MMD, moyamoya disease; SD, standard deviation.
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nine cases of cerebral aneurysm. The control patients
were matched according to gender; however, their overall
age was older than that of patients with MMD, as patients
with MMD tend to be younger than those with cerebral
aneurysm (75% of control patients), which mainly affects
middle-aged individuals.
Sample Collection
All CSF samples were collected after obtaining informed
written consent from the patients following approval
from the Nagoya University School of Medicine Ethical
Review Board. CSF was obtained for all subjects in the
same manner during the first phase of the operative
procedure after the arachnoid membrane was dissected.
Blood contamination was avoided as much as possible
by carefully performing hemostasis. CSF sampling was
performed at least 4 weeks after the stroke event asso-
ciated with MMD or other pathogenesis. Within 2 h of
collection, the CSF sample was stored in 1.5-ml cryo-
tubes, centrifuged at 3000 rpm for 10 min at 4°C, and
the supernatants were frozen and stored in approxi-
mately 1-ml aliquots at -80°C until analysis.
Sample preparation and analysis
CSF preparation
The CSF samples in each cryo-tube were thawed in
water at room temperature, then kept on ice and well
agitated before subjected to ProteinChip array. The sam-
ples were diluted by each binding/washing buffer (0.2 M
citrate-phosphate, pH 5 or 7, or 0.2 M Tris-HCl, pH 9)
at a final ratio of 1/5.
ProteinChip array pretreatment
Q10 (strong anion exchanger) ProteinChip array (Bio-
Rad Laboratories) was used for protein profile analysis.
The chips were equilibrated prior to the CSF sample
addition with binding/washing buffer for 2 × 5 min.
ProteinChip array preparation
Diluted CSF (20 μl) was applied on a spot in the chip and
incubated for 40 min in a humid box at room tempera-
ture. After allowing the sample to bind, the remaining
sample was removed from all spots by immediately wash-
ing the array with the corresponding binding/washing buf-
fer 3 × 5 min. The arrays were rinsed with 150 μl distilled
water twice and allowed to air-dry for 15 min. Then, 1 μl
saturated energy absorbing molecule (EAM) solution
(sinapinic acid in 50% acetonitrile and 0.5% trifluoroacetic
acid) was applied to each spot and again allowed to air-dry
before analysis by the ProteinChip reader.
SELDI-TOF-MS and data acquisition
Mass spectral processing
The protein mass spectral data was generated with Pro-
teinChip System 4000 SELDI-TOF mass spectrometer
(Enterprise version; Bio-Rad Laboratories) using auto-
mated data collection protocol with Ciphergen Express
version 3.0.6 software interface (Bio-Rad Laboratories).
The optimal laser intensity range for spectra generation
was predetermined to be 2800 to 3500 nJ by manual
laser shots. For determining the maximum protein peak
yield and spectral reproducibility, data were collected
between 0 and 100 kDa with the ion focus mass set to
7000 Da and the matrix attenuation to 1000 Da. After
two initial warming shots, 53 points equally distributed
o v e rt h ec h i ps p o ts u r f a c ew e r el a s e d1 0t i m e sf o ri o n i -
zation of the proteins.
Peak detection of SELDI protein profiles
All the obtained spectra were internally mass-calibrated
and normalized to the total ion current of an m/z value
more than 1000 for avoiding the signal interference
from EAM. Expression difference mapping (EDM) was
performed automatically using Ciphergen Express data
management software version 3.0.6 under the following
conditions: signal/noise ratio of 5 or higher for the first
pass, 2 for the second pass, and presentation in at least
20% of spectra for identification.
Data analysis for single biomarker candidate protein
identification
A comparative analysis of protein profiles of the MMD
and control groups using univariate analysis was per-
formed for single biomarker candidate protein identifi-
cation under each pH condition. P values were
calculated based on the Mann-Whitney U test for non-
parametric data or two-tailed t-test for parametric data,
and the area under the receiver operation characteristic
(ROC) curve (AUC) of each peak cluster was deter-
mined by Ciphergen Express data management software
version 3.0. A P value of less than 0.05 was considered
statistically significant.
Data mining using classification and regression trees
(CART)
Generally, stability and accuracy of the prediction model
were tested to assign a training set and test set from the
data set. However, as the size of the data set in this
study was too small to construct an independent valida-
tion set, a tree-based model was adopted to make a pre-
diction model for multi-biomarker candidate protein
identification. This model applies non-linear regression
analysis and has recently been used broadly for data
mining. CART for data mining was applied as described
previously [26,27]. A decision tree was generated using
entropy and the Gini index for calculating a node [28].
Branching of the tree is created based on the values
(node) calculated by these indices and pruned using the
complexity parameter. In this study, the complexity
parameter was set to 0.01. This analysis was performed
with the R software environment for statistical comput-
ing (R Development Core Team, Vienna, Austria).
Araki et al. BMC Neurology 2010, 10:112
http://www.biomedcentral.com/1471-2377/10/112
Page 3 of 9Peak reproducibility
Reproducibility of peak intensity and mass accuracy were
evaluated using pooled CSF samples from two individuals
from the control group. The coefficient of variance (CV)
was calculated using randomly selected multiple protein
peaks over the experiment as previously described
[29,30]. For the assessment of peak reproducibility of the
SELDI profiles, both the intra-assay (spot-to-spot) and
inter-assay (chip-to-chip) CV were determined.
Results
Peak reproducibility
In this study, the intra-assay (spot-to-spot) CV was
17.38% for peak intensity and 0.11% for mass accuracy.
The inter-assay (chip-to-chip) CV was 25.11% for peak
intensity and 0.14% for mass accuracy, indicating accep-
table reproducibility of the spectra.
SELDI-TOS-MS protein profiling and data analysis
SELDI-TOF-MS analysis for CSF samples
After making the EDM cluster, the CSF samples were
analyzed in a binding/washing buffer with three different
pH conditions (pH 5, 7 and 9). Between 1 to 100 kDa
m/z, 54, 40 and 59 m/z peak clusters were generated for
the pH 5, 7 and 9 conditions, respectively; the respective
minimum peaks were 1027.73, 1041.82 and 1026.39, and
the respective maximum peaks were 93797.02, 94648.40
and 95278.35.
Univariate analysis using EDM data for identification of
single biomarker candidate proteins
For identification of single biomarker candidates in each
pH condition, univariate analysis was performed using
EDM data. Table 2 shows 34 biomarker candidate pro-
teins differentially expressed among the MMD and con-
trol groups (P < 0.05); m/z was less than 10 kDa and
ranged from 1041.03 to 50989.55, for which 15 proteins
were significant (P < 0.01). Of the 34 biomarker candi-
dates, 15, 5 and 4 were detected under pH 5, 7 and 9
conditions, respectively. The mean ROC AUC value of
each cluster was 0.7723, ranging from 0.7 to 0.9. Among
these protein candidates, 19 were up-regulated and 15
were down-regulated in the MMD group compared to
the control group. There were 11 peak clusters thought
to be originated from 5 m/z peak clusters; m/z 4473.46
at pH 5 and 4475.10 at pH 7, m/z 4589.34 at pH 9,
4588.73 at pH 5 and 4588.87 at pH 7, m/z 6941.48 at
pH 9 and 6942.96 at pH 7, m/z 13882.19 at pH 9 and
13877.49 at pH 7. Within these clusters, there is a mini-
mal difference in m/z (<5.3). Spectra of representative
single biomarker candidates under each pH condition
using SELDI ProteinChip analysis are shown in Figure 1
for each CSF sample from the MMD and control
groups. All proteins were up-regulated in the MMD
group. A box-whisker plot of the peak intensities for
representative single biomarker candidate proteins in
each group is demonstrated in Figure 2. For the MMD
group, the mean peak intensity of m/z 4473 at pH 5
was 22.64 ± 9.72 (mean ± standard deviation), that of
m/z 4588 at pH 7 was 56.67 ± 28.42, and that of m/z
4746 at pH 9 was 44.94 ± 18.76; those of the control
group were 11.78 ± 5.16 30.62 ± 8.42, and 20.37 ±
10.24, respectively. All peak intensities of each cluster
were significantly larger in the MMD than control
group (P < 0.01).
Table 2 Single biomarker candidates from univariate
analysis of CSF sample comparison of MMD and control
groups






1.60E-04 4746.76 pH 9 0.9000 up
5.32E-04 4566.71 pH 5 0.8583 down
6.14E-04 4473.46
a pH 5 0.8750 up
1.08E-03 4157.65 pH 9 0.8250 up
1.41E-03 4589.34
b pH 9 0.8250 up
1.41E-03 50989.55 pH 9 0.8417 down
1.41E-03 4588.73
b pH 5 0.8250 up
3.09E-03 4588.87
b pH 7 0.8000 up
3.09E-03 6941.48
d pH 9 0.8083 down
3.51E-03 6942.96
d pH 7 0.8167 down
7.24E-03 9656.51 pH 5 0.8000 up
7.24E-03 13754.72 pH 5 0.7750 up
8.12E-03 4809.94
c pH 5 0.7667 down
9.11E-03 2406.55 pH 5 0.7667 down
9.11E-03 13882.19
e pH 9 0.7583 down
1.02E-02 9728.65 pH 5 0.7750 up
1.14E-02 6228.21 pH 5 0.7333 down
1.27E-02 13877.49
e pH 7 0.7917 down
1.42E-02 21299.65 pH 5 0.7583 down
1.58E-02 5781.11 pH 5 0.7500 up
1.76E-02 14060.91 pH 9 0.7417 down
1.76E-02 4695.40 pH 5 0.7417 down
1.95E-02 6240.88 pH 9 0.7500 up
2.16E-02 28095.59 pH 9 0.7583 down
2.40E-02 4475.1
a pH 7 0.7500 up
2.40E-02 7250.89 pH 7 0.7250 up
2.40E-02 3516.49 pH 9 0.7250 up
2.93E-02 6888.58 pH 5 0.7250 up
3.23E-02 3681.83 pH 9 0.7250 up
3.56E-02 1041.03 pH 9 0.7000 up
3.91E-02 7146.84 pH 5 0.7333 down
4.30E-02 4811.33
c pH 9 0.7000 up
4.71E-02 1061.94 pH 9 0.7250 up
4.71E-02 34344.75 pH 5 0.7083 down
a-eValues with the same lower-case letter indicate clusters most likely derived
from the same proteins. *P < 0.05, Mann-Whitney U test
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Page 4 of 9Figure 1 Mass spectra of representative single biomarker candidate proteins in CSF under different pH conditions. Protein profiles of
the MMD and control groups were generated using Q10 (strong anion exchanger) array. For each pH condition, the upper two spectra are
protein profiles obtained between m/z 2,000 and 10,000, and the lower two spectra are expansions showing the peak intensities around m/z
4473, 4588 and 4476 for pH 5, 7 and 9, respectively. All representative peaks (red arrows) are larger for the MMD than control group under each
pH condition, as determined by SELDI-TOF-MS.
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CART analysis was undergone to discriminate patients
with MMD from control patients using a single biomar-
ker obtained by SELDI-TOF-MS under different pH
conditions (pH 5, 7 and 9) (Figure 3). The analysis cor-
rectly classified all 20 patients with MMD at pH 5 and
19 of them at pH 7 and 9; all control patients were clas-
sified correctly under all pH conditions. As shown in
Figure 4, CART analysis was able to classify 19 of the
20 patients with MMD and all 12 of the control
patients.
Discussion
Purpose of this study
D i a g n o s i so fM M Di sc u r r e n t l yo n l ya c h i e v a b l eb yr a d i -
ological features using cerebral angiography or magnetic
resonance imaging/angiography. However, characteris-
tics of MMD-mimicking vascular conditions are fre-
quently encountered on radiological imaging in the
clinical setting [31,32], sometimes rendering indetermi-
nate diagnosis of MMD. In this pilot study, we utilized
novel biomarker candidate proteins identified in CSF
samples by SELDI-TOF-MS to aid in the definite diag-
nosis of MMD. Based on our results, a mechanism for
these biomarkers in association with the pathogenesis of
MMD could be elucidated.
Study design
Many factors have limited the advancement of basic
research on MMD. Some of these include low mortality
rate, difficulty of obtaining surgical specimens from the
internal carotid artery or related intracranial vessels, and
lack of an appropriate animal model [33]. Recent
investigations of MMD have focused on its epidemiol-
ogy [2-4], pathology [9,10], relationship with endothelial
progenitor cells [16,17] and genetics [5-8], identifying
some potential mechanisms and development pathways
of this condition. However, their findings constitute only
part of the underlying cause of MMD. As the CSF con-
tacts the extracellular space of the brain, it contains an
obvious source of biomarkers which should reflect cen-
tral neuro-pathologic impairments of the brain. With
the development of global proteomic research for bio-
marker discovery [34], previous studies have proposed
many biomarkers, especially for neuro-degenerative dis-
eases, although mainly using two-dimensional polyacry-
lamide electrophoresis [35,36]. A variety of recent
proteomic techniques based on MS have also been uti-
lized, including electrospray ionization tandem MS,
matrix-assisted laser desorption/ionization MS and
SELDI MS, with mechanically different methods of ion
separation, mass accuracy and resolution, along with dif-
ferent pretreatments of low abundant proteins, such as
found in the CSF [37,38]. Our study focused on proteo-
mic analysis using SELDI-TOF-MS, a high-throughput,
reliable technique which allows large numbers of patient
samples to be investigated with a low sample volume
scale, simple maneuvering and comparatively shorter
time than other methods. SELDI technology has been
used for a number of clinical situations and sample
types to identify biomarker pro t e i ne x p r e s s i o np a t t e r n s
which discriminate patients with a certain disease from
control individuals [39].
We tested Q10 (strong anion exchanger) ProteinChip
array to capture a wide variety of proteins derived from
the CSF, including physiologically active substances
Figure 2 Peak intensity of representative single biomarker candidate proteins in the MMD and control groups. Peak intensities of
representative single biomarker candidate proteins detected using SELDI-TOF-MS are significantly larger in the MMD than control group under
each pH condition (m/z 4473, 4588 and 4476 for pH 5, 7 and 9, respectively). The box-whisker plots indicate the median value (thick line) and
the 25th (lower line of box) and 75th (upper line of box) percentile; T bars indicate the 10th and 90th percentile. The p values between the
groups were calculated using Mann-Whitney U test. *P < 0.01.
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Page 6 of 9ionized under physiological pH (7.2 - 7.4). We also
tested CM10 (weak cation exchanger) ProteinChip array,
which can indiscriminately detect many kinds of bio-
marker proteins, although no meaningful results were
obtained using our methodology (data not shown). Q10
ProteinChip array was therefore applied in this study
using a binding/washing buffer at pH 5, 7, and 9,
around physiological pH conditions. This is the first
study to identify biomarker candidate proteins by
SELDI-TOF-MS using the CSF of patients with MMD.
Evaluation of the results in this study
Definite diagnostic tool for discrimination of patients with
MMD and control patients
In the course of our study using SELDI-TOF-MS, 34
candidates of single biomarker proteins within the range
of 1-50 kDa were generated with Q10 ProteinChip
array. SELDI technology can feasibly resolve these low
molecular weight proteins which cannot be resolved by
other current proteomic methods like two-dimensional
electrophoresis. As a definite diagnostic tool of MMD,
analysis of these proteins could adequately discriminate
between the MMD and control groups (P < 0.05 and
ROC AUC 0.7 - 0.9). CART analysis enabled this discri-
mination to provide a prediction model with relatively
higher sensitivity and specificity, although the study
population was too small to construct independent
training and test set subjects. Therefore, a larger study
population is needed for validation of these results.
Comparison analysis using over-expressed/down-regulated
proteins in the CSF of patients with MMD
Previous studies have suggested several growth factors
that are related to angiogenesis. These include transform-
ing growth factor-b [11], basic fibroblast growth factor
[12], hepatocyte growth factor [13], hypoxia inducible
factor-1 [14] and vascular endothelial growth factor [15],
with m/z 83133, 55960, 42005, 92670, 38200 Da, respec-
tively. As these angiogenic factors have relatively larger
molecular weights (>10 kDa), they are more accessible to
purification and exact identification using conventional
methodologies. For a further understanding of the
Figure 3 CART analysis using peaks obtained by SELDI-TOF-MS to discriminate between patients with MMD and control patients. The
decision tree was constructed using CSF samples from 32 patients with MMD and control patients. The classification is determined starting at
the roof node, following by appropriate splitting decisions based on the peak intensity at each node. If the peak intensity is lower than the
cutoff intensity value, the left node is selected. This splitting process is continued until no further classification is achieved and terminal nodes
are produced. Using m/z 4473, 2406 and 6338 peaks (pH 5), m/z 4588 and 7250 peaks (pH 7), and m/z 4746 and 1044 peaks (pH 9), CART for
Q10 ProteinChip was applied to identify patients with MMD and control patients. The analysis correctly classified all 20 patients with MMD under
pH 5 condition and 19 of 20 under the pH 7 and 9 conditions; all 12 control patients were classified under all pH conditions.
Figure 4 CART analyses using all 34 single biomarker
candidate proteins. CART was analyzed for 34 single biomarker
candidate proteins identified in the CSF under each pH condition
(pH 5, 7 and 9) to discriminate patients with MMD from control
patients. This analysis correctly classified 19 of 20 patients with
MMD and all 12 control patients based on the peak intensities of
the m/z 4473 peak (pH 5) and m/z 4588 peak (pH 7).
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cant m/z peaks were elucidated on the proteome-wide
database level. Candidate protein (peptide) biomarkers
were inferred using the TagIdent tool (http://au.expasy.
org/tools/tagident.html) from the UniProt Knowledge-
b a s e( S w i s s - P r o ta n dT r E M B L )d a t a b a s e sb a s e do nt h e
definite molecular mass; the retrieval conditions were set
as pI 1.0 to 14.0 and m/z ± 0.5%. Six proteins (peptides)
had corresponding molecular weights of two candidates,
m/z 4473 and 4588, obtained by CART analysis from the
34 single biomarker candidate proteins (Table 3). Exact
identification of biomarker proteins is undoubtedly
advantageous, although as in this study, purification is
difficult to achieve with a lack of abundant samples from
clinical subjects. Moreover, protein identification requires
specialized techniques, and ah i g h l ys e n s i t i v em e t h o di s
needed to properly identify the target protein, especially
those with a low molecular weight.
Conclusions
Several novel biomarker candidate proteins differentially
expressed in patients with MMD and control patients
were identified using a recently developed proteomic
approach. This is a pilot study for CSF proteomics of
MMD using SELDI technology. Multi-biomarker analy-
sis using CART made the prediction models more speci-
fic and exhibited two m/z panels as a discriminative tool
for the definite diagnosis of MMD. For further under-
standing of the pathogenesis of MMD, a larger number
of CSF samples for validation of the analysis and well-
defined methodology and techniques for exact identifi-
cation of biomarkers are essential.
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